Detecting ALK, ROS1 and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small cell lung cancer patients using RNA-based techniques.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13468
Abstract: ALK, ROS1 and RET fusions and MET∆ex14 variant associate with response to targeted therapies in non-small cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid biopsies, which are often… read more here.
Keywords: alk ros1; ros1 ret; met ex14; liquid biopsies ... See more keywords
Costs of ALK, ROS1, EGFR, and KRAS testing in non–small cell lung cancer: About different strategies in France
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Cytopathology"
DOI: 10.1002/cncy.21919
Abstract: We read with interest the review by Pisapia et al about perspectives on ALK and ROS1 testing for cytologic lung cancer samples. In addition to fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), we agree… read more here.
Keywords: cancer; egfr kras; alk ros1; pathology ... See more keywords
Immunocytochemical Detection of ALK and ROS1 Rearrangements in Lung Cancer Cytological Samples.
Sign Up to like & getrecommendations! Published in 2021 at "Methods in molecular biology"
DOI: 10.1007/978-1-0716-1278-1_12
Abstract: The detection of molecular alterations such as ROS1 and ALK rearrangements is performed as part of the diagnosis of advanced-stage lung adenocarcinoma. These alterations allow the treatments with tyrosine kinase inhibitors. Cytological samples are very… read more here.
Keywords: detection; alk; cytological samples; alk ros1 ... See more keywords
First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2017.04.032
Abstract: Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to 2nd-generation ALK inhibitors. Lorlatinib (PF-06463922) (6) is a 3rd-generation macrocyclic ALK-TKI that demonstrates many advantages over 2nd-generation ALK inhibitors.… read more here.
Keywords: inhibitor; alk; alk ros1; generation ... See more keywords
Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2021.113259
Abstract: Aiming to develop ALK/ROS1 dual inhibitors overcoming ceritinib-resistant G1202R mutant, a dedicated structure-guided modification campaign was conducted based on ALK co-crystal structures. Twenty eight diarylaminopyrimidine (DAAP) analogues possessing furan or tetrahydrofuran group were designed and… read more here.
Keywords: alk ros1; diarylaminopyrimidine; compound; ros1 dual ... See more keywords
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.05.019
Abstract: INTRODUCTION Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Odds ratios (OR) and hazard ratios (HR) of TE were calculated from meta-analysis and time-to-event analysis… read more here.
Keywords: nsclc patients; analysis; alk ros1; ros1 ... See more keywords
Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2162044
Abstract: ABSTRACT Introduction Oncogene-addicted non-small cell lung cancer (NSCLC) patients present a high incidence of CNS metastases either at diagnosis or during the course of the disease. In this case, patients present with worse prognosis and… read more here.
Keywords: non small; alk ros1; ros1 ntrk; small cell ... See more keywords
Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Pathology"
DOI: 10.1136/jclinpath-2019-206152
Abstract: Aims Several predictive biomarkers of response to specific inhibitors have become mandatory for the therapeutic choice in non-small-cell lung cancer (NSCLC). In most lung cancer patients, the biological materials available to morphological and molecular diagnosis… read more here.
Keywords: kinase; alk ros1; ros1; rearrangement ... See more keywords
Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Pathology"
DOI: 10.1136/jclinpath-2021-207490
Abstract: The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses to detect genetic rearrangements… read more here.
Keywords: ros1; non small; alk ros1; lung cancer ... See more keywords
Abstract 3168: Overcoming acquired drug resistance by TPX-0005, an ALK, ROS1 and pan-TRK inhibitor
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3168
Abstract: The inevitable development of clinical drug resistance presents a common challenge for targeted cancer therapy. In non-small cell lung cancer (NSCLC) patients with ALK and ROS1 rearrangements, the emergence of mutations in the targeted oncogenes… read more here.
Keywords: cancer; tpx 0005; resistance; alk ros1 ... See more keywords
Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical chemistry"
DOI: 10.1373/clinchem.2016.265314
Abstract: BACKGROUND Anaplastic lymphoma receptor tyrosine kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), and ret proto-oncogene (RET) fusions are present in 5%-7% of patients with advanced non-small-cell lung cancer (NSCLC); their accurate identification is… read more here.
Keywords: advanced non; ret fusions; alk ros1; ros1 ... See more keywords